Literature DB >> 6982786

Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.

L W Brox, E Pollock, A Belch.   

Abstract

Adenosine and deoxyadenosine toxicity was examined in colony assay systems for human T lymphocytes, B lymphocytes, and granulocytes. In the absence of deoxycoformycin, an adenosine deaminase inhibitor, no growth inhibition was observed in the three systems with concentrations of adenosine or deoxyadenosine of at least 200 microM. Deoxycoformycin itself had no growth-inhibitory effect at concentrations of at least 10 micrograms/ml. Combinations of deoxycoformycin (1 microgram/ml) and either adenosine or deoxyadenosine gave growth inhibition in all three systems. Deoxyadenosine was the most toxic in all the systems, the LD50 values being 20-25 microM. The LD50 values for adenosine were 45-55 microM. There was no evidence of selective toxicity by adenosine or deoxyadenosine with these three colony assay systems. In the T-lymphocyte colony system deoxyadenosine appeared to be toxic to both the inducer/helper and the suppressor/cytotoxic T-lymphocyte subpopulations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982786     DOI: 10.1007/BF00296762

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.

Authors:  C E Cass; T H Au-Yeung
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

2.  Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.

Authors:  C A Koller; B S Mitchell; M R Grever; E Mejias; L Malspeis; E N Metz
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

3.  Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes.

Authors:  M S Weiner; C Bianco; V Nussenzweig
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

4.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

5.  Deoxyadenosine metabolism and toxicity in cultured L5178Y cells.

Authors:  J K Lowe; B Gowans; L Brox
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

6.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

Review 7.  Toxicity of naturally occurring purine deoxyribonucleosides.

Authors:  J F Henderson; F W Scott; J K Lowe
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

8.  Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia.

Authors:  M D Minden; R N Buick; E A McCulloch
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

9.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.

Authors:  E L Reinherz; P C Kung; G Goldstein; R H Levey; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Colony formation by normal and malignant human B-lymphocytes.

Authors:  C A Izaguirre; M D Minden; A F Howatson; E A McCulloch
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

View more
  2 in total

Review 1.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

2.  Treatment of multiple myeloma with deoxycoformycin.

Authors:  A R Belch; J F Henderson; L W Brox
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.